Lilly U.K. Evista Ads With Breast Cancer Claim Are Misleading - PMCPA
Executive Summary
U.K. journal advertisements for Lilly's osteoporosis treatment Evista (raloxifene) that make a breast cancer claim have been declared "misleading" by the Prescription Medicines Code of Practice Authority Appeal Board.